Cambridge Investment Research Advisors
NBIX icon

Cambridge Investment Research Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
+6,718
New +$997K ﹤0.01% 2188
2025
Q1 		– Sell
-1,482
Closed -$202K – 3586
2024
Q4 		$202K Buy
+1,482
New +$183K ﹤0.01% 3190
2024
Q3 		– Sell
-2,549
Closed -$351K – 3490
2024
Q2 		$351K Buy
2,549
+77
+3% +$10.6K ﹤0.01% 2578
2024
Q1 		$341K Buy
+2,472
New +$338K ﹤0.01% 2601

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Cambridge Investment Research Advisors's NBIX Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 6,718 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #2188 among its holdings. This is a return to the name: Cambridge Investment Research Advisors previously reported a position in NBIX as recently as Q4 2024.

Cambridge Investment Research Advisors first reported a position in NBIX in Q1 2024 and has held it in 4 quarters since. 253 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Cambridge Investment Research Advisors held 6,718 shares of Neurocrine Biosciences worth $1.13M as of Q2 2026.
  • Neurocrine Biosciences was a new Cambridge Investment Research Advisors position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2188 holding.
  • Cambridge Investment Research Advisors first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 4 quarters since.
  • 253 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.